



Safety and Monitoring Solution
Fact Sheet

The Safety and Monitoring Solution is a fraud, waste and abuse prescription therapy monitoring solution which evaluates appropriateness of controlled substances and other targeted drugs. This solution supports safe and appropriate utilization, with prescriber awareness via mail, as necessary.

To learn more about how this solution can work for your plan, please contact your CVS Caremark Account Representative.

<p align="center">Edit Criteria</p>	<p>Edits will have certain thresholds, with a corresponding risk score. Edits can be customized, but generally include:</p> <ul style="list-style-type: none"> • Number of Controlled Substance Prescribers • Number of Controlled Substance Pharmacies • Total Number of Controlled Substance Claims • Total Number of Concurrent Controlled Substances • Total Number of Concurrent Controlled Substances Providers • Excessive Utilization • Geographic Location • Total Claim Cost
<p align="center">Target Drugs</p>	<ul style="list-style-type: none"> • Narcotic/narcotic combinations • Anxiolytics • Sedative/hypnotics • Non-benzodiazepine sedatives/hypnotics • Muscle relaxants • CNS stimulants • Other controlled substances
<p align="center">Process Flow</p>	<p>System Review: Claims are run through a complex algorithm, high-risk plan participants are identified and profiles are generated.</p> <p>Clinical Review: On a monthly and quarterly basis clinical pharmacists evaluate generated profiles and may contact applicable prescribers or pharmacies to obtain more clinical data regarding plan participants' prescription use.</p> <p>Intervention: If it is observed that there is a potential misuse or safety concern, CVS Caremark sends prescribers letters noting the observed behavior and plan participants' profiles. If the client has a medical case management program or investigation unit, upon request, CVS Caremark is able to refer applicable cases for additional intervention and investigation.</p> <p>Follow Up: Pharmacists conduct follow up reviews and generate letters for targeted plan participants quarterly, for up to nine months.</p>